Switching From Omalizumab to OMLYCLO in Asthma or Hives
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This study follows patients with severe asthma or chronic hives who are already on omalizumab (Xolair) and are switching to a very similar, lower-cost biosimilar called OMLYCLO. It aims to see if the switch works well in real-world practice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have severe asthma or chronic spontaneous urticaria (long-lasting hives)
- You have been treated with the original omalizumab (Xolair) for at least 6 months
- Your disease has been stable for the last 3 months (e.g., no asthma attacks needing steroids, or hive scores well-controlled)
- Your doctor has decided to switch you to OMLYCLO (a biosimilar version of omalizumab) as part of your regular care
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how diet and oxidative stress (a type of cell damage) affect the severity of chronic hives and how well patients respond to the medication omalizumab (Xolair). It may help find ways to improve treatment by understanding these factors.
This study tests whether adding a bacterial extract called OM-85 to your usual antihistamine helps control chronic hives better than antihistamines alone. It is an observational study, meaning the treatment is decided by your doctor, not assigned randomly.
This study tests a new oral medication (TLL-018) for people with chronic hives that don't fully go away with standard antihistamines. It aims to see if the drug reduces itching and hives better than placebo.
This trial tests a new daily pill called TLL-018 (a JAK inhibitor) for people with chronic hives that still cause symptoms despite taking antihistamines. It aims to see how fast it relieves itching and hives.
This Phase 4 study looks at whether extending the time between omalizumab injections can still control chronic spontaneous hives (CSU). It may help some people need fewer injections while keeping symptoms under control.
This trial tests whether stopping omalizumab for a short time (or using it differently) can be safe for adults with severe allergic asthma who are doing well. It may help some people avoid long-term injections, but only if asthma remains well controlled.
Hear when a new Allergic Asthma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.